title: Control of disease activity and tumor size after introduction of pegvisomant in a lanreotide-resistant acromegalic patient.
abstract: We report on a 30-year-old female acromegalic patient treated with the growth hormone (GH) receptor antagonist pegvisomant at a low dose after the failure of long-acting lanreotide, neurosurgery and radiotherapy treatment to restore IGF-1 levels. The combination treatment was well tolerated and produced a dramatic improvement in the patient's condition (reduction in visual field defects, relief of headache and excessive perspiration), normalization of IGF-I levels and a considerable decrease in tumor size, enabling a dramatic decrease in lanreotide dosage and, ultimately, its withdrawal.
authors: Service d'endocrinologie-nutrition, hôpital Sud, université Picardie-Jules-Verne, centre hospitalier universitaire, 80054 Amiens, France.
authors: Salha
authors: S
authors: Fendri
authors: Pelin
authors: P
authors: Karaca
authors: Evelyne
authors: E
authors: Tiev
authors: Michael
authors: M
authors: Buchfelder
authors: Jean-Daniel
authors: JD
authors: Lalau
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D000236:Adenoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D019008:Drug Resistance, Neoplasm; D005260:Female; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D019382:Human Growth Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D012074:Remission Induction; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D019382:Human Growth Hormone; D013004:Somatostatin; C406545:pegvisomant